Marine Biomedical
Marine Biomedical is an Australian biotech developing PearlBone™, a nacre-derived bone graft substitute for orthopaedic, trauma, and reconstructive surgeons. The pre-revenue company operates from Broome, Western Australia, and is advancing through U.S. FDA 510(k) regulatory clearance.
- Company typePrivate
- Founded2021
- HeadquartersBroome, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Marine Biomedical firmographics
Firmographics- Name
- Marine Biomedical
- Legal name
- Marine Biomedical Pty Ltd
- Website
- https://marinebiomedical.com.au
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Marine Biomedical is an Australian biotech developing PearlBone™, a nacre-derived bone graft substitute for orthopaedic, trauma, and reconstructive surgeons. The pre-revenue company operates from Broome, Western Australia, and is advancing through U.S. FDA 510(k) regulatory clearance.
- Ownership category
- akta.pro rank
Marine Biomedical industry classification
Industry- Product category
- Orthopaedic Medical Devices (Bone Graft Substitutes)
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
Keywords
Where Marine Biomedical is headquartered
LocationHeadquarters
- HQ city
- Broome
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Marine Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- PearlBone™ Bone Graft Products: Marine Biomedical is pre-revenue with PearlBone™ currently undergoing regulatory review. Once FDA and TGA approvals are secured, the company will commercialize its nacre-derived bone graft substitute products for orthopaedic, trauma, and reconstructive surgery applications globally.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Marine Biomedical product offering
Product offeringCore offering
Marine Biomedical develops and manufactures PearlBone™, a marine-derived bone graft substitute produced from nacre (mother of pearl) harvested from sustainably sourced Western Australian pearl oyster shells. The lead formulation, PearlBone™ Putty, is engineered as a biocompatible, osteoconductive scaffold that fills bone voids and defects, supports new bone formation, and gradually integrates with the patient's native bone in orthopaedic, trauma, and reconstructive surgery applications. The product is manufactured at an in-house GMP cleanroom facility in Broome, Western Australia, and is currently progressing through FDA 510(k) review in the U.S. and TGA pathway in Australia.
Product overview
Marine Biomedical operates a single-product portfolio centered on PearlBone™, a marine-derived bone graft substitute. The core product PearlBone™ is a biomaterial derived from nacre (mother of pearl) found in Western Australian pearl oyster shells. The lead commercial formulation is PearlBone™ Putty, designed for orthopaedic, trauma, and reconstructive surgery applications. Both products share the same nacre-derived base technology and are manufactured at the company's GMP facility in Broome, Western Australia.
Differentiator
Problem solved
Functional benefit
Brands
- PearlBone™: Marine-derived bone graft substitute product derived from nacre (mother of pearl) sourced from Western Australian pearl oysters. PearlBone™ is designed as a biocompatible scaffold to support natural bone regeneration in orthopaedic, trauma and reconstructive surgery applications. The lead product is PearlBone™ Putty.
Products and services
- PearlBone™ PearlBone™ is a marine-derived bone graft substitute developed from nacre (mother of pearl) sourced from sustainably certified Western Australian silver-lipped pearl oysters. It is engineered as a biocompatible, osteoconductive scaffold designed to fill bone voids and defects, support new bone formation, and integrate with the body's natural bone matrix in orthopaedic, trauma, and reconstructive surgery applications.
- PearlBone™ Putty PearlBone™ Putty is the lead commercial formulation of Marine Biomedical's nacre-derived bone graft substitute. It is a marine-derived calcium carbonate biomaterial developed from pearl oyster shell, engineered into a porous, biocompatible scaffold designed to fill bone voids and defects, support new bone formation, and integrate with the body's natural bone matrix. The material is gradually resorbed and replaced with new bone as part of the natural healing process.
Quantifiable outcome
- Preclinical studies demonstrated PearlBone™ Putty was resorbed and replaced by new immature woven cancellous bone comparable to predicate device used extensively over past 20 years. No adverse tissue reactions in 3-month study period.
- +1 more outcomes
Companies that use Marine Biomedical
Customer profileSegments3 records
Ideal customer profiles1 record
Marine Biomedical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Marine Biomedical partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Willie Creek PearlscoreMarine Biomedical was established through a partnership with Willie Creek Pearls, a renowned Broome pearling business. The partnership ensures a consistent supply of mother of pearl (nacre) from sustainably certified Western Australian silver-lipped pearl oysters for PearlBone™ manufacturing.
- University of Western AustraliacorePearlBone™ was developed through research at UWA's Medical School. Professor Minghao Zheng (Winthrop Professor of Orthopaedic Research) is the inventor of PearlBone™ and a Marine Biomedical founding partner. Dr Rui Ruan co-invented the technology. Research expertise through UWA's Medical School continues to support product development.
- MTPConnect WA Life Sciences Innovation HubminorMTPConnect WA Life Sciences Innovation Hub Director Kevin Pfleger expressed support for Marine Biomedical's potential to unlock marine-derived biomedical applications in Australia.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Marine Biomedical competitors and assessment
Company assessmentEmerging players
- SurGenTec: Emerging orthobiologics company developing bone graft and spine products for orthopaedic surgery. Comparable emerging player competing in the same bone void-filling niche with specialty surgeon-focused products.
- Mesoblast: Regenerative medicine company commercializing cell-based therapies for inflammatory and orthopaedic conditions. Comparable as a specialty regenerative-medicine player pursuing regulatory approval in musculoskeletal indications, though at a later commercial stage.
- Celling Biosciences: Regenerative medicine company commercializing cellular and orthobiologic products for spine and orthopaedic applications. Comparable emerging peer with similar specialty orthobiologics positioning and surgeon-channel focus.
Direct peers
- BoneSupport: Specialist bone graft substitute company commercializing CERAMENT, an injectable bone graft for orthopaedic trauma and infection. Closest direct competitor to PearlBone™, targeting the same surgical bone void-filling use cases with a comparable synthetic/biologic hybrid technology.
- Orthocell: Australian regenerative medicine company developing orthopaedic biologic products. Direct commercial partner and strategic investor in Marine Biomedical, with overlapping focus on cartilage, tendon, and bone repair. Comparable in stage and therapeutic area, making it the closest functional peer.
- Xtant Medical: Orthobiologics company focused on bone graft substitutes and spinal hardware for orthopaedic and trauma surgery. Direct competitor in the bone graft substitute category with comparable surgeon customer base.
Broad incumbents
- MTF Biologics: Large US tissue bank supplying allograft-based bone graft substitutes and sports medicine tissues. Relevant incumbent competing on the allograft side of the same bone void-filling market Marine Biomedical is entering.
- Smith & Nephew: Global orthopaedic and sports medicine player with bone graft substitute and regenerative products. Comparable as a large incumbent in orthopaedic surgery distribution channels targeted by Marine Biomedical.
- Stryker: Major orthopaedic and trauma device company offering bone graft substitutes and surgical biologics alongside implants. Competes in the same surgical bone repair channels as PearlBone™, though as part of a much broader portfolio.
- Medtronic (Spinal & Biologics): Global medical device leader with INFUSE Bone Graft and broader spinal/orthobiologics portfolio. Broad incumbent competing in the same bone graft substitute category and setting surgeon adoption standards.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Marine Biomedical social profiles
Digital presenceMarine Biomedical compliance and trust
Trust signalCompliance2 records
Marine Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Marine Biomedical leadership team
Management profileNumber of profiles
Profiles14 records
Marine Biomedical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Marine Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Marine Biomedical
What does Marine Biomedical do?
Marine Biomedical develops and manufactures PearlBone™, a marine-derived bone graft substitute produced from nacre (mother of pearl) harvested from sustainably sourced Western Australian pearl oyster shells. The lead formulation, PearlBone™ Putty, is engineered as a biocompatible, osteoconductive scaffold that fills bone voids and defects, supports new bone formation, and gradually integrates with the patient's native bone in orthopaedic, trauma, and reconstructive surgery applications. The product is manufactured at an in-house GMP cleanroom facility in Broome, Western Australia, and is currently progressing through FDA 510(k) review in the U.S. and TGA pathway in Australia.
Is Marine Biomedical a public or private company?
Marine Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Marine Biomedical founded?
Marine Biomedical was founded in 2021. It employs 1 to 10 people.
Where is Marine Biomedical based?
Marine Biomedical is headquartered in Broome, Australia, in the Oceania region.
How does Marine Biomedical make money?
One revenue line is on record: pearlBone™ Bone Graft Products.
Who are Marine Biomedical's main competitors?
Emerging players on record are SurGenTec, Mesoblast and Celling Biosciences. Direct peers are BoneSupport, Orthocell and Xtant Medical. Broad incumbents are MTF Biologics, Smith & Nephew, Stryker and Medtronic (Spinal & Biologics).
Does Marine Biomedical have an API?
No public API is recorded for Marine Biomedical.
What industry is Marine Biomedical in?
Marine Biomedical's product category is Orthopaedic Medical Devices (Bone Graft Substitutes). Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3842.